Congresses
Discover our science and data shared at congresses around the world. This section includes scientific and promotional information related to Alnylam’s licensed medicines in the UK and their relevant therapeutic areas.
Information on investigational products or unlicensed indications is not included on this website.
The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].
UK healthcare professionals seeking details which cannot not be found below, may contact Alnylam Medical, where enquiries will be handled in accordance with UK Medical Information requirements.
Transthyretin Amyloidosis (ATTR)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025
Acute Hepatic Porphyria (AHP)
American Association for the Study of Liver Diseases (AASLD) 2025
Primary Hyperoxaluria Type 1 (PH1)
American Society of Nephrology (ASN) 2025
Primary Hyperoxaluria Type 1 (PH1)
European Society for Paediatric Nephrology (ESPN) 2025
Acute Hepatic Porphyria (AHP)
International Porphyrias Symposium (IPS) 2025
Transthyretin Amyloidosis (ATTR)
Heart Failure Society of America (HFSA) 2025
Transthyretin Amyloidosis (ATTR)
European ATTR Amyloidosis Meeting (EU-ATTR) 2025
Primary Hyperoxaluria Type 1 (PH1)
International Paediatric Transplant Association (IPTA) 2025
Primary Hyperoxaluria Type 1 (PH1)
European Society for Paediatric Urology (ESPU) 2025
Acute Hepatic Porphyria (AHP)
International Congress of Inborn Errors Metabolism (ICIEM) 2025
Transthyretin Amyloidosis (ATTR)
European Society of Cardiology (ESC) 2025
Primary Hyperoxaluria Type 1 (PH1)
